Home/Filings/4/0001209191-23-034886
4//SEC Filing

MOEBIUS HANS 4

Accession 0001209191-23-034886

CIK 0001620463other

Filed

Jun 5, 8:00 PM ET

Accepted

Jun 6, 7:35 PM ET

Size

9.4 KB

Accession

0001209191-23-034886

Insider Transaction Report

Form 4
Period: 2023-06-02
MOEBIUS HANS
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-06-027,8820 total
    Exercise: $1.35Exp: 2029-08-14Common Stock (7,882 underlying)
  • Award

    Common Stock

    2023-05-18$2.41/sh+7,764$18,71173,600 total
  • Exercise/Conversion

    Common Stock

    2023-06-02$1.35/sh+7,882$10,64181,482 total
Footnotes (4)
  • [F1]The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2022 through May 18, 2023. This transaction is also exempt under Rule 16b-3(c).
  • [F2]The Purchase Period ended May 18, 2023 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2022.
  • [F3]In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2023.
  • [F4]One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.

Issuer

Athira Pharma, Inc.

CIK 0001620463

Entity typeother

Related Parties

1
  • filerCIK 0001822494

Filing Metadata

Form type
4
Filed
Jun 5, 8:00 PM ET
Accepted
Jun 6, 7:35 PM ET
Size
9.4 KB